[Supporting Information]

Pd(II)-catalyzed C(sp³)-H arylation of amino acid derivatives with click-triazoles as removable directing

group

Guofu Zhang,^a Xiaoqiang Xie,^a Jianfei Zhu,^a Shasha Li,^a Chengrong Ding^a and Ping Ding^b
^aCollege of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, People's Republic of China.
^bSchool of Public Health, Central South University, Changsha 410078, People's Republic of China. *dingcr@zjut.edu.cn*.

Table of Contents

Substrate Synthesis	pageS2-S6
---------------------	-----------

Experimental Sections	age S7-S	59
-----------------------	----------	----

Characterization Data for Productspa	age S10-S17
--------------------------------------	-------------

NMR Spectra for Products	page S18-S40
--------------------------	--------------

General Experimental

Unless otherwise noted all commercial materials were used without further purification. Solvents were used after purification directed by *Purification of Laboratory Chemicals, 6th Ed.* Column chromatography was performed with silica gel (300-400 mesh) produced by Qingdao Marine Chemical Factory, Qingdao (China). NMR spectra were recorded on Bruker AVANCE III 500MHz instrument with TMS as internal standard. Coupling constants were reported in Hertz (Hz).

Experimental Sections



eq1: NaN₃(110.0 mol, 7.15 g) and 1-Bromohexane(100.0 mol, 16.51 g) were added in DMSO(200 mL) at room temperature and the reaction solutions were stirred overnight. When the reaction was finished, H₂O(50 mL) was added in the solution and extracted with methyl tertiary butyl ether(3×200 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the 1-azidohexane as a colorless oil(70%, 8.90 g).

eq2: Amino acid (20.0 mmol), finely ground phthalic anhydride(20 mmol), toluene (45 mL), and Et_3N (2.0 mmol, 0.28 mL) were added to a 100 mL round bottom flask. After refluxing the reaction mixture overnight, concentrated hydrochloric acid (0.4 mL) and water (50 mL) were added in the solution. The crude product was extracted with ethyl acetate and dried over anhydrous Na_2SO_4 . The organic solvent was removed and recrystallized by MeOH/H₂O to give the N-phthalimido-protected amino acid.

eq3: N-Phthalimido-protected amino acid (10.0 mmol), thionyl chloride (30.0 mmol) and four drops of DMF were added in toluene at 82 °C for 4 h. After the reaction, the excess of thionyl chloride and toluene was removed in vacuo, and the crude acyl chloride dissolved in dry CH_2Cl_2 (15 mL) used for next reaction.

eq4: To a vigorously stirring solution of 2-propynylamine (10.0 mmol) and triethylamine(12.0 mmol) in CH_2Cl_2 (30 mL) at 0 °C, the crude acyl chloride in CH_2Cl_2 was added dropwise slowly. Then the reaction mixture was stirred for 5 h at rt. The reaction was quenched with saturated NaHCO₃. The aqueous layer was extracted with CH_2Cl_2 . The combined organic extracts was concentrated under reduced pressure and the crude product was purified by column chromatography on silica gel(*n*-hexane/ethyl acetate (v/v 1:1)).

eq5: The alkyne amide compound(10.0 mmol), 1-azidohexane(20.0 mmol), CuSO₄(0.5 mmol), sodium ascorbate (1.0 mmol) were added in 30 mL acetone/H₂O(v/v 1:1) solution at N₂ atmosphere. The reaction mixture was stirred overnight at rt. After the reaction, ammonia hydroxide(10 mL) was added in the solution and extracted with ethyl acetate. The organic extracts was concentrated under reduced pressure and the crude product was purified by column chromatography on silica gel(*n*-hexane/ethyl acetate (v/v 1:2)).

Characterization Data for Amino Acid Derivatives



1a: ¹H NMR (500 MHz, CDCl₃): δ 0.88(t, *J* = 6.5 Hz, 3H), 1.18(d, *J* = 3.0 Hz, 3H), 1.30(s, 6H), 1.85(t, *J* = 6.5 Hz, 2H), 4.25(t, *J* = 7.0 Hz, 2H), 4.44(d, *J* = 3.0 Hz, 2H), 4.92(q, *J* = 7.0 Hz, 1H), 7.47 (s, 1H), 7.59(s, 1H), 7.69-7.72(dd, *J*₁ = 5.5 Hz, *J*₂ = 3.0 Hz, 2H), 7.78-7.81(dd, *J*₁ = 5.5 Hz, *J*₂ = 3.0 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 15.2, 22.4, 26.1, 30.1, 31.1, 35.1, 49.0, 50.5, 123.4, 132.0, 134.1, 167.7, 169.4. HRMS (ESI) m/z calcd for C₂₀H₂₅N₅O₃ [M]⁺ 383.2030; found 383.2032.



2a: ¹H NMR (500 MHz, CDCl₃): δ 0.88(t, *J* = 6.8 Hz, 3H), 1.31 (s, 6H), 1.83(d, *J* = 5.0 Hz, 6H), 1.86(t, *J* = 6.7 Hz, 2H), 4.27(t, *J* = 7.3 Hz, 2H), 4.44(d, *J* = 6.0 Hz, 2H), 7.31 (d, *J* = 5.5 Hz, 1H), 7.64(s, 1H), 7.66-7.68(m, 2H), 7.71-7.72(m, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 24.8, 26.1, 30.1, 31.1, 35.1, 50.5, 61.4, 122.7, 122.9, 132.0, 133.9, 144.5, 168.5, 173.3. HRMS (ESI) m/z calcd for C₂₁H₂₇N₅O₃ [M]⁺ 397.2187; found 397.2174.



3a: ¹H NMR (500 MHz, CDCl₃): δ 0.89(t, *J* = 7.0 Hz, 3H), 1.20 (d, *J* = 7.0 Hz, 3H), 1.32(d, *J* = 7.0 Hz, 6H), 1.90(t, *J* = 7.0 Hz, 2H), 2.84(q, *J* = 7.0 Hz, 1H), 3.73(q, *J* = 7.0 Hz, 1H), 3.93(dd, *J*₁ = 13.5 Hz, *J*₂ = 7.5 Hz, 1H), 4.31 (t, *J* = 7.5 Hz, 2H), 4.41-4.50(m, 2H), 6.49(s, 1H). 7.55(s, 1H), 7.72(dd, *J*₁ = 5.5 Hz, *J*₂ = 3.0 Hz, 2H), 7.82(dd, *J*₁ = 5.5 Hz, *J*₂ = 3.0 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.3, 15.6, 21.9, 25.8, 29.9, 30.8, 34.4, 39.4, 41.0, 50.2, 122.2, 123.3, 131.6, 134.3, 144.6, 168.4, 174.0. HRMS (ESI) m/z calcd for C₂₁H₂₇N₅O₃ [M]⁺ 397.2187; found 397.2178.

Chiral HPLC Data

HPLC Conditions:

Chiral stationary phase: HPLC Chiralpack® AD-Hcolumn (*n*-hexane/isopropanol = 55:45,

0.70 mL/min) Wavelength = 254 nm tr = 8.973 min (major), >93%ee.



Area% report for 1a:

	Retention	Area	% Area	Height	% Height
	Time				
1	7.834	100234	2.34	4110	3.33
2	8.973	4175524	97.66	119134	96.67

References

- (1) Alvarez, S. G.; Alvarez, M. T. Synthesis 1997, 413
- (2) He, J.; Li, S. H.; Deng, Y. Q.; Fu, H. Y.; Laforteza, B. N.; Spangler, J. E.; Homs, A.; Yu, J. Q. Science 2014, 343, 1216.
- (3) Tran, L. D.; Daugulis, O. Angew. Chem., Int. Ed. 2012, 51, 5188.

Optimization of Reaction Conditions

	O O TAH NH + O	Pd(II) additiv OMe solven 2a	e t			∕TAH NH ──────────────────────────────────
entry	catalyst	additive	solvent	temp.(°C)	time(h)	yield ^b (%)
1	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	DCE	100	5	39
2	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	DMF	100	5	trace
3	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	o-xylene	100	5	ND^{c}
4	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	toluene	100	5	ND
5	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	THF	100	5	ND
6	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	t-BuOH	100	5	24
7	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	t-AmylOH	100	5	31
8	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	HFIP	100	5	93
9	Pd(TFA) ₂ (10mol%)	AgOAc(0.3mol)	HFIP	100	5	50
10	PdCl ₂ (10mol%)	AgOAc(0.3mol)	HFIP	100	5	57
11	Pd(PPh ₃) ₄ (10mol%)	AgOAc(0.3mol)	HFIP	100	5	trace
12	Pd(OAc) ₂ (10mol%)	Ag ₂ CO ₃ (0.3mol)	HFIP	100	5	27
13	Pd(OAc) ₂ (10mol%)	AgNO ₃ (0.3mol)	HFIP	100	5	15
14	Pd(OAc) ₂ (10mol%)	AgSbF ₆ (0.3mol)	HFIP	100	5	ND
15	Pd(OAc) ₂ (10mol%)	Ag ₂ O(0.3mol)	HFIP	100	5	ND
16	Pd(OAc) ₂ (5mol%)	AgOAc(0.3mol)	HFIP	100	24	56
17	Pd(OAc) ₂ (10mol%)	AgOAc(0.2mol)	HFIP	100	24	68
18	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	HFIP	100	24	76 ^d
19	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	HFIP	80	24	42
20	Pd(OAc) ₂ (10mol%)	AgOAc(0.3mol)	HFIP	100	3	70

^{*a*}The reactions were conducted with 0.20 mmol of **1a**, 10.0 mol% Pd(OAc)₂, 0.30 mmol of **2a**, 0.30 mmol of additive, 1.0 ml of solvent and stirred for 5h unless other noted. ^{*b*}Determined by ¹H NMR spectroscopy using 1,3,5-trimethoxybenzene as an internal standard. ^{*c*}ND= Not Detected. ^{*d*}0.2 mmol of **2a**.

General Procedure for Pd(II)-Catalyzed C(sp³)-H Arylation of Amino Acid Derivatives.

 $Pd(OAc)_2(0.04 \text{ mmol})$, AgOAc (0.60 mmol), alkyl iodine (0.60 mmol), **1** (0.40 mol), HFIP(2 mL) were introduced into a 15 mL seal tube equipped with a magnetic stirrer in air. The mixture was fiercely stirred at 100 °C for 5 h. After cooling to room temperature, the reaction was diluted with ethyl acetate (15 mL) and then filtered through a pad of Celite and washed by ethyl acetate (50 mL). The organic solvent was evaporated under vacuum and the crude product was purified by column chromatograph using silica gel with *n*-hexane/ethyl acetate (v/v 1:2) as eluent.

Gram-Scale Synthesis and Removal of the TAH group



Pd(OAc)₂(0.30 mmol, 67.4mg), AgOAc(4.50 mmol, 0.75g), 1-iodo-4-nitrobenzene **2i**(4.50 mmol, 1.12g), **1a**(3.0 mol, 1.15g), HFIP(15 mL) were introduced into a 100 mL seal tube equipped with a magnetic stirrer in air. The mixture was fiercely stirred at 100 °C for 24 h. After cooling to room temperature, the reaction was diluted with ethyl acetate (40 mL) and then filtered through a pad of Celite and washed by ethyl acetate (100 mL). The organic solvent was evaporated under vacuum and the crude product was purified by column chromatograph using silica gel with *n*-hexane/ethyl acetate (v/v 1:2) as eluent, and **3ai** was obtained in 93% yield(1.41 g).



Substrate **3ai**(2.79 mmol, 1.41g), BF₃·Et₂O (20.30 mmol, 2.50 mL) were added in dry methanol(30 mL), and the solution was fiercely stirred at 100 °C for 10 h. After cooling to room temperature, Et₃N (30.10 mmol, 4.20 mL) was added dropwise to the reaction solution with stirring. The organic solvent was evaporated under vacuum and the crude product was purified by column chromatograph using silica gel with *n*-hexane/ethyl acetate (v/v 20:1 to 2:1) as eluent. The organic solvent was evaporated

under vacuum and the product 4ai was obtained of a colorless oil (86% yield, 0.86g).



Substrate **3ai** (2.43 mmol, 0.86 g) was dissolved in MeOH (44 mL), then 80% Ethylenediamine (10.0 mmol, 0.60g) was added. The reaction was stirred at room temperature for 20 h and the solvent was removed in vacuo. Saturated aqueous NaHCO₃ was added, and the solution extracted with ethyl acetate(3×50 mL). The organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated.



The residue was was dissolved in 1,4-dioxane(15 mL), and 10% aq. NaHCO₃(10 mL) was added. The mixture was cooled to 0 °C and Fmoc–Cl (2.52mmol, 0.65g) was added into the solution. After 1.5 h at 0 °C and 10 h at room temperature, H₂O and EtOAc was added to the reaction mixture. The aqueous layer was then extracted with EtOAc twice and the combined organic layers were washed with brine, dried over MgSO₄, filtered and concentrated. the crude product was purify by column chromatography with *n*-hexane/ethyl acetate (v/v 3:1 to 2:1) as eluent.



The substrate was dissolved in THF (10 mL). The solution was cooled to 0 °C, and a cold solution of LiOH·H₂O (3.0 mmol, 0.126g) in H₂O (10 mL) were added. The reaction was maintained at 0 °C for 1 hour. Then the reaction was acidified with HCl (1 N) and extracted with ethyl acetate(4×30 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by column chromatography using CH₂Cl₂/MeOH (10:1) as the eluent to afford the desired product **5ai** (49% for three steps, 0.51 g).

Characterization Data for Products



3aa (Table 2, entry 1): ¹H NMR (500 MHz, CDCl₃): δ 0.89(s, 3H), 1.32(s, 6H), 1.91(s, 2H), 3.43(t, J = 11.0 Hz, 1H), 3.53(d, J = 10.5 Hz, 1H), 3.68(s, 3H). 4.34(s, 2H), 4.57(s, 2H), 5.06(s, 1H), 6.67(d, J = 7.5 Hz, 2H), 7.03(d, J = 7.5 Hz, 2H), 7.66(s, 2H), 7.72(s, 2H), 7.79(s, 1H), 7.91(s, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.3, 26.0, 29.8, 31.0, 33.7, 34.2, 51.5, 55.1, 55.2, 113.9, 123.4, 124.0, 128.6, 129.9, 131.6, 134.1, 158.3, 167.8, 169.1; HRMS (ESI) m/z calcd for C₂₇H₃₁N₅O₄ [M]⁺ 489.2449; found 489.2467.



0.90(t, J = 6.5 Hz, 3H), 1.33(s, 6H), 1.92(s, 2H), 3.41(dd, $J_1 = 13.5$ Hz, $J_2 = 10.5$ Hz, 1H), 3.60(dd, $J_1 = 13.5$ Hz, $J_2 = 4.5$ Hz, 1H), 3.74(s, 3H), 4.35(t, J = 7.5 Hz, 2H), 4.61(s, 2H), 5.26(dd, $J_1 = 10.5$ Hz, $J_2 = 5.5$ Hz, 1H), 6.69(t, J = 7.0 Hz, 1H), 6.75(d, J = 7.5 Hz, 1H), 6.98(d, J = 6.0 Hz, 1H), 7.12(t, J = 8.0 Hz, 2H), 7.68(dd, $J_1 = 5.0$ Hz, $J_2 = 3.0$ Hz, 3H), 7.75(t, J = 5.5 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.1, 30.0, 30.4, 31.1, 34.8, 51.0, 52.4, 55.2, 110.2, 120.5, 123.3, 125.0, 128.5, 130.9, 131.7, 134.0, 157.5, 167.8, 169.2; HRMS (ESI) m/z calcd for C₂₇H₃₁N₅O₄ [M]⁺ 489.2449; found 489.2459.

3ab (Table 2, entry 2): ¹Η NMR (500 MHz, CDCl₃): δ



3ac (Table 2, entry 3): ¹H NMR (500 MHz, CDCl₃): δ 0.89(t, J = 7.0 Hz, 3H), 1.30-1.35(m, 9H), 1.88(t, J = 7.0 Hz, 2H), 3.43-3.54(m, 2H), 3.88-3.93(m, 2H), 4.30(t, J = 7.5 Hz, 2H), 4.47-4.56(m, 2H), 5.08(dd, $J_I = 11.0$ Hz, $J_2 = 6.0$ Hz, 1H), 6.68(d, J = 8.5 Hz, 2H). 7.03(d, J = 8.5 Hz, 2H), 7.13(t, J = 5.5 Hz, 1H), 7.56(s, 1H), 7.68(dd, $J_I = 5.5$ Hz, $J_2 = 3.0$ Hz, 2H), 7.75(dd, $J_I = 5.5$ Hz, $J_2 = 3.0$ Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 14.7, 22.4, 26.1, 30.1, 31.1, 33.9, 35.1, 50.6, 55.5, 63.3, 114.6, 122.6, 123.5, 128.4, 129.9, 131.5, 134.2, 144.2, 157.8, 167.9, 168.8; HRMS (ESI) m/z calcd for C₂₈H₃₃N₅O₄ [M]⁺ 503.2605; found 503.2627.



3ad (Table 2, entry 4): ¹H NMR (500 MHz, CDCl₃): δ

0.89(t, J = 6.5 Hz, 3H), 1.31(s, 6H), 1.86(dd, $J_1 = 13.5$ Hz, $J_2 = 7.0$ Hz, 2H), 3.49-3.62(m, 2H), 4.27(t, J = 7.5 Hz, 2H), 4.50(s, 2H). 5.12(q, J = 5.5 Hz, 1H), 7.10-7.16(m, 5H), 7.25(s, 1H), 7.58(s, 1H), 7.66(dd, $J_1 = 5.5$ Hz, $J_2 = 3.5$ Hz, 2H), 7.73(dd, $J_1 = 5.5$ Hz, $J_2 = 3.5$ Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.1, 30.0, 31.1, 34.6, 51.0, 52.3, 123.4, 126.8, 128.5, 128.9, 131.6, 134.1, 136.8, 167.8, 168.9; HRMS (ESI) m/z calcd for C₂₆H₂₉N₅O₃ [M]⁺ 459.2343; found 459.2320.



3ae (Table 2, entry 5): ¹H NMR (500 MHz, CDCl₃): δ 0.90(t, J = 5.5 Hz, 3H), 1.33(s, 6H), 1.90(s, 2H), 3.47-3.59(m, 2H), 4.32(t, J = 7.0 Hz, 2H), 4.54(s, 2H). 5.09(dd, $J_I = 11.5$ Hz, $J_2 = 5.0$ Hz, 1H), 6.84(t, J = 8.0 Hz, 2H), 7.10(dd, $J_I = 8.5$ Hz, $J_2 = 6.0$ Hz, 2H), 7.60(s, 1H), 7.70(t, J = 4.0 Hz, 2H), 7.75(t, J = 5.0 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.3, 26.1, 30.2, 31.1, 34.1, 35.3, 50.4, 55.2, 120.9, 122.2, 123.6, 130.6, 131.4, 131.8, 134.3, 135.9, 144.2, 167.8, 168.3. ¹⁹F NMR (376 MHz, DMSO- d_6): δ -115.75; HRMS (ESI) m/z calcd for C₂₆H₂₈FN₅O₃ [M]⁺ 477.2249; found 477.2267.



3af (Table 2, entry 6): ¹H NMR (500 MHz, CDCl₃): δ 0.90(t, J = 6.5 Hz, 3H), 1.33(s, 6H), 1.92(t, J = 7.0 Hz, 2H), 3.47-3.60(m, 2H), 4.35(t, J = 7.0 Hz, 2H), 4.52-4.62(m, 2H). 5.09(dd, $J_I = 11.5$ Hz, $J_2 = 5.0$ Hz, 1H), 7.08(d, J = 8.5 Hz, 2H), 7.12(t, J = 8.5 Hz, 2H), 7.54(s, 1H), 7.67(s, 1H), 7.70(dd, $J_I = 6.0$ Hz, $J_2 = 3.5$ Hz, 2H), 7.76(dd, $J_I = 5.5$ Hz, $J_2 = 2.5$ Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.1, 29.9, 31.0, 33.9, 34.6, 51.2, 55.0, 123.3, 123.6, 128.7, 130.3, 131.5, 132.7, 134.4, 135.2, 143.6, 167.7, 168.6; HRMS (ESI) m/z calcd for C₂₆H₂₈ClN₅O₃ [M]⁺ 493.1953; found 493.1939.



3ag (Table 2, entry 7): ¹Η NMR (500 MHz, CDCl₃): δ

0.89(t, J = 6.0 Hz, 3H), 1.31(s, 6H), 1.86(s, 2H), 3.48-3.58(m, 2H), 4.27(t, J = 6.5 Hz, 2H), 4.47(s, 2H). 5.09(dd, $J_1 = 11.5$ Hz, $J_2 = 5.0$ Hz, 1H), 7.01(d, J = 8.5 Hz, 2H), 7.26(s, 1H), 7.52(s, 1H), 7.56(s, 1H), 7.68(t, J = 3.0 Hz, 2H), 7.73(t, J = 6.5 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.3, 26.1, 30.1, 31.1, 34.1, 35.1, 50.5, 55.0, 120.8, 123.5, 130.6, 131.4, 131.6, 134.2, 135.8, 167.7, 168.4; HRMS (ESI) m/z calcd for C₂₆H₂₈BrN₅O₃ [M]⁺ 537.1448; found 537.1451.



3ah (Table 2, entry 8): ¹Η NMR (500 MHz, CDCl₃): δ

0.90(t, J = 5.5 Hz, 3H), 1.32(s, 6H), 1.87(s, 2H), 3.50-3.61(m, 2H), 4.28(t, J = 7.0 Hz, 2H), 4.50(dd, $J_1 = 6.0$ Hz, $J_2 = 1.5$ Hz, 2H). 5.12(dd, $J_1 = 11.5$ Hz, $J_2 = 6.0$ Hz, 1H), 6.98(t, J = 8.0 Hz, 2H), 7.06(dd, $J_1 = 8.0$ Hz, $J_2 = 2.0$ Hz, 1H), 7.12(dd, $J_1 = 9.0$ Hz, $J_2 = 1.5$ Hz, 1H), 7.53(s, 1H), 7.71(dd, $J_1 = 5.5$ Hz, $J_2 = 2.0$ Hz, 2H), 7.78(dd, $J_1 = 5.5$ Hz, $J_2 = 3.0$ Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.2, 28.4, 30.2, 31.2, 35.3, 50.5, 53.6, 119.0, 119.3, 122.3, 123.6, 127.5, 131.5, 132.3, 132.4, 134.4, 167.6, 168.0. ¹⁹F NMR (376 MHz, DMSO- d_6): δ -114.56; HRMS (ESI) m/z calcd for C₂₆H₂₇BrFN₅O₃ [M]⁺ 555.1354; found 555.1365.



3ai (Table 2, entry 9): ¹Η NMR (500 MHz, CDCl₃): δ

0.90(t, J = 6.0 Hz, 3H), 1.32(s, 6H), 1.86(s, 2H), 3.65-3.74(m, 2H), 4.26(t, J = 7.0 Hz, 2H), 4.48(s, 2H). 5.16(d, J = 7.5 Hz, 1H), 7.33(d, J = 8.5 Hz, 2H), 7.56(s, 2H), 7.70(s, 2H), 7.73(s, 2H), 8.02(d, J = 8.5 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.5, 26.1, 30.2, 31.2, 34.6, 35.2, 50.7, 54.7, 123.7, 123.8, 129.9, 131.4, 134.6, 144.8, 147.1, 167.7, 168.0; HRMS (ESI) m/z calcd for C₂₆H₂₈N₆O₅ [M]⁺ 504.2194; found 504.2186.



3aj (Table 2, entry 10): ¹Η NMR (500 MHz, CDCl₃): δ

0.88(t, J = 7.5 Hz, 3H), 1.29(s, 6H), 1.83(t, J = 6.5 Hz, 2H), 3.63-3.78(m, 2H), 4.24(t, J = 7.0 Hz, 2H), 4.43(t, J = 5.0 Hz, 2H). 5.15(q, J = 5.5 Hz, 1H), 7.34(t, J = 7.5 Hz, 1H), 7.50(d, J = 7.0 Hz, 1H), 7.51(s, 1H), 7.66(dd, $J_1 = 6.0$ Hz, $J_2 = 3.5$ Hz, 2H), 7.71(dd, $J_1 = 6.0$ Hz, $J_2 = 3.5$ Hz, 2H), 7.97(dd, $J_1 = 9.0$ Hz, $J_2 = 1.5$ Hz, 1H), 8.02(s, 1H), 8.05(s, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.1, 30.1, 31.1, 34.3, 34.8, 50.7, 54.7, 122.0, 123.5, 123.9, 129.5, 131.4, 134.3, 135.2, 139.3, 148.2, 167.7, 168.1; HRMS (ESI) m/z calcd for C₂₆H₂₈N₆O₅ [M]⁺ 504.2194; found 504.2217.



3ak (Table 2, entry 11): ¹Η NMR (500 MHz, CDCl₃): δ

 $0.90(t, J = 6.5 \text{ Hz}, 3\text{H}), 1.32(s, 6\text{H}), 1.89(t, J = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_1 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 4.05(dd, J_2 = 5.5 \text{ Hz}, 2\text{H}), 3.67-3.73(m, 1\text{H}), 3.67$

14.5 Hz, $J_2 = 4.5$ Hz, 1H), 4.30(t, J = 7.5 Hz, 2H), 4.54(d, J = 5.5 Hz, 2H), 5.31(dd, $J_1 = 11.0$ Hz, $J_2 = 4.5$ Hz, 1H), 6.90(s, 1H), 7.21(dd, $J_1 = 7.5$ Hz, $J_2 = 2.5$ Hz, 1H), 7.33-7.35(m, 2H), 7.57(s, 1H), 7.71(dd, $J_1 = 5.0$ Hz, $J_2 = 3.0$ Hz, 2H), 7.77(dd, $J_1 = 5.0$ Hz, $J_2 = 3.0$ Hz, 2H), 8.00 (dd, $J_1 = 7.0$ Hz, $J_2 = 1.5$ Hz, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, , 22.4, 26.1, 30.1, 31.1, 32.6, 35.2, 50.53, 53.5, 122.6, 123.4, 125.4, 128.3, 131.5, 132.8, 132.9, 133.3, 134.2, 149.0, 167.7, 168.0; HRMS (ESI) m/z calcd for C₂₆H₂₈N₆O₅ [M]⁺ 504.2194; found 504.2170.



O **3al (Table 2, entry 12):** ¹H NMR (500 MHz, CDCl₃): δ 0.89(t, J = 6.5 Hz, 3H), 1.30(s, 6H), 1.85(s, 2H), 2.49(s, 3H), 3.59-3.68(m, 2H), 4.25(t, J = 7.5 Hz, 2H), 4.46(t, J = 15.0 Hz, 2H), 5.15(q, J = 5.5 Hz, 1H), 7.23(d, J = 7.5 Hz, 2H), 7.55(s, 2H), 7.66(dd, $J_1 = 6.0$ Hz, $J_2 = 3.5$ Hz, 2H), 7.71(dd, $J_1 = 5.5$ Hz, $J_2 = 3.5$ Hz, 2H), 7.74(d, J = 8.5 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.1, 26.5, 30.1, 31.1, 34.6, 35.1, 50.4, 54.8, 123.5, 128.6, 129.1, 131.4, 134.2, 135.8, 142.6, 167.8, 168.3, 197.7; HRMS (ESI) m/z calcd for C₂₈H₃₁N₅O₄ [M]⁺ 501.2449; found 501.2465.



3am (Table 2, entry 13): ¹H NMR (500 MHz, CDCl₃): δ 0.89(t, J = 6.5 Hz, 3H), 1.32(s, 6H), 1.87(t, J = 7.0 Hz, 2H), 3.59-3.69(m, 2H), 4.27(t, J = 7.0 Hz, 2H), 4.49(t, J = 5.0 Hz, 2H), 5.15(q, J = 5.5 Hz, 1H), 7.26(s, 1H), 7.32(s, 1H), 7.42(d, J = 8.0 Hz, 2H), 7.54(s, 1H), 7.69(dd, $J_I = 5.5$ Hz, $J_2 = 3.0$ Hz, 2H), 7.75(dd, $J_I = 5.5$ Hz, $J_2 = 3.0$ Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.1, 30.1, 31.1, 34.4, 35.1, 50.4, 54.9, 123.5, 123.7, 128.2, 128.5, 129.2, 131.4, 134.3, 134.5, 167.8, 168.2. ¹⁹F NMR (376 MHz, DMSO- d_6): δ -62.99; HRMS (ESI) m/z calcd for C₂₇H₂₈F₃N₅O₃ [M]⁺ 527.2217; found 527.2234.



3an (Table 2, entry 14): ¹H NMR (500 MHz, CDCl₃): $\delta 0.87(t, J = 6.5 \text{ Hz}, 3\text{H}), 1.27(s, 6\text{H}), 1.80(s, 2\text{H}), 3.56-3.68(m, 2\text{H}), 3.80(s, 3\text{H}), 4.18(t, J = 7.5 \text{ Hz}, 2\text{H}), 4.38(s, 2\text{H}), 5.13(dd, J_I = 11.0 \text{ Hz}, J_2 = 5.0 \text{ Hz}, 1\text{H}), 7.17(d, J = 8.5 \text{ Hz}, 2\text{H}), 7.54(s, 1\text{H}), 7.60(t, J = 4.0 \text{ Hz}, 2\text{H}), 7.65(t, J = 4.0 \text{ Hz}, 2\text{H}), 7.78(d, J = 8.0 \text{ Hz}, 2\text{H}), 8.07(s, 1\text{H}).$ ¹³C NMR (125 MHz, CDCl₃): $\delta 13.8, 22.3, 26.1, 30.0, 31.1, 34.6, 35.0, 50.4, 51.9, 54.8, 122.7, 123.3, 128.7, 128.9, 129.7, 131.5, 134.0, 142.5, 144.4, 166.7, 167.7, 168.3; HRMS (ESI) m/z calcd for C₂₈H₃₁N₅O₅ [M]⁺ 517.2398; found 517.2399.$



3ao (Table 2, entry 15): ¹H NMR (500 MHz, CDCl₃): δ 0.91(t, J = 6.5 Hz, 3H), 1.35(s, 6H), 1.99(s, 2H), 3.52(t, J = 11.0 Hz, 1H), 3.70(dd, $J_I = 13.0$ Hz, $J_2 = 4.5$ Hz, 1H), 4.46(d, J = 6.0 Hz, 2H), 4.69(d, J = 13.0 Hz, 1H), 4.79(d, J = 13.0 Hz, 1H), 5.20(dd, $J_I = 11.0$ Hz, $J_2 = 4.5$ Hz, 1H), 7.22(d, J = 8.0 Hz, 2H), 7.30(t, J = 7.5 Hz, 1H), 7.36-7.40(m, 4H), 7.48(d, J = 7.5 Hz, 2H), 7.66(dd, $J_I = 5.0$ Hz, $J_2 = 3.0$ Hz, 2H), 7.75(dd, $J_I = 5.0$ Hz, $J_2 = 3.0$ Hz, 2H), 8.03(s, 1H), 8.38(s, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 26.2, 30.1, 31.1, 34.3, 35.1, 50.6, 55.3, 122.7, 123.5, 126.9, 127.2, 128.7, 129.3, 131.5, 134.2, 135.8, 139.6, 140.5, 144.2, 167.8, 168.7; HRMS (ESI) m/z calcd for C₃₂H₃₃N₅O₃ [M]⁺ 535.2656; found 535.2663.



3ap (Table 2, entry 16): ¹H NMR (500 MHz, CDCl₃):

δ 0.89(t, J = 6.5 Hz, 3H), 1.30(s, 6H), 1.83(t, J = 7.5 Hz, 2H), 3.84(dd, $J_1 = 15.0$ Hz, $J_2 = 11.0$ Hz, 1H), 4.18-4.24(m, 2H), 4.40-4.50(m, 2H). 5.30(dd, $J_1 = 10.5$ Hz, $J_2 = 5.0$ Hz, 1H), 7.15(t, J = 3.0 Hz, 2H), 7.43-7.53(m, 4H), 7.61-7.67(m, 5H), 7.78(d, J = 7.5 Hz, 1H), 8.09(d, J = 7.5 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 25.9, 29.6, 30.0, 31.7, 33.5, 52.5, 54.1, 123.2, 123.4, 125.1, 125.8, 126.4, 127.3, 127.8, 128.9, 131.6, 132.9, 133.8, 134.1, 167.7, 169.3; HRMS (ESI) m/z calcd for C₃₀H₃₁N₅O₃ [M]⁺ 509.2500; found 509.2510.



3bj: ¹H NMR (500 MHz, CDCl₃): δ 0.89(dd, J_1 = 10.0

Hz, $J_2 = 6.5$ Hz, 3H), 1.30(d, J = 10.0 Hz, 6H), 1.83(s, 3H), 1.86(d, J = 9.0 Hz, 2H), 3.40-3.64(m, 1H), 3.89-4.03(m, 1H), 4.12-4.28(m, 3H), 4.35-4.42(m, 1H), 7.30-7.37(m, 1H), 7.54-7.61(m, 3H), 7.65-7.68(m, 3H), 7.69-7.86(m, 1H), 8.00-8.04(m, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 13.9, 22.4, 24.8, 26.1, 30.1, 31.2, 34.9, 39.7, 40.5, 50.4, 122.3, 123.0, 123.1, 125.6, 129.0, 131.4, 134.0, 134.3, 136.9, 148.0, 168.5, 168.9; HRMS (ESI) m/z calcd for $C_{27}H_{30}N_6O_5$ [M]⁺ 518.2350; found 518.2363.



3cg: ¹H NMR (500 MHz, CDCl₃): δ 0.90(t, J = 7.0 Hz, 3H), 1.34(t, J = 5.5 Hz, 6H), 1.90(s, 2H), $2.83(dd, J_1 = 13.0 \text{ Hz}, J_2 = 4.0 \text{ Hz}, 1\text{H})$, $3.02(dd, J_1 = 13.0 \text{ Hz})$ = 14.0 Hz, J_2 = 10.0 Hz, 1H), 3.11(s, 1H), 3.83(dd, J_1 = 14.0 Hz, J_2 = 5.0 Hz, 1H), 3.96(dd, J_1 = 14.0 Hz, J₂ = 7.5 Hz, 1H), 4.44(d, J = 6.5 Hz, 4H), 7.10(d, J = 7.5 Hz, 2H), 7.31(d, J = 8.5 Hz, 2H), 7.69(q, J = 3.0 Hz, 3H), 7.75(dd, $J_1 = 5.5$ Hz, $J_2 = 3.5$ Hz, 3H). ¹³C NMR (125 MHz, CDCl₃): § 13.9, 22.3, 25.9, 29.5, 31.0, 32.3, 35.6, 40.0, 47.0, 53.3, 120.2, 123.3, 130.9, 131.4, 131.9, 134.1, 137.3, 168.4, 173.1; HRMS (ESI) m/z calcd for C₂₇H₃₀BrN₅O₃ [M]⁺ 551.1604; found 551.1608.



4ai: ¹H NMR (500 MHz, CDCl₃): 3.64-3.73(m, 2H), 3.80(s,

3H). 5.19(dd, $J_1 = 11.0$ Hz, $J_2 = 6.0$ Hz, 1H), 7.36(d, J = 8.5 Hz, 2H), 7.73(q, J = 2.5 Hz, 2H), 7.80(q, J = 2.5 Hz, 2H), 8.07(d, J = 9.0 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 34.7, 51.5, 53.0, 123.7, 123.9, 129.9, 131.4, 134.4, 144.5, 147.1, 167.3, 168.7.



5ai: ¹H NMR (500 MHz, DMSO- d_6): 3.02(dd, $J_1 = 14.0$ Hz, J_2 = 11.0 Hz, 1H), $3.25(dd, J_1 = 14.5 Hz, J_2 = 4.5 Hz, 1H)$, 4.15-4.30(m, 4H), 7.26-7.31(m, 2H), 7.40(t, J = 8.0 Hz, 2H), 7.55(d, J = 9.0 Hz, 2H), 7.62(dd, $J_1 = 7.0$ Hz, $J_2 = 3.0$ Hz, 2H), 7.82(d, J = 8.5 Hz, 1H), 7.88(d, J = 7.5 Hz, 2H), 8.15(d, J = 8.5 Hz, 2H), 12.9(s, 1H).. ¹³C NMR (125 MHz, CDCl₃): δ 36.2, 45.6, 54.7, 65.6, 120.0, 123.2, 125.1, 127.0, 127.5, 130.4, 140.7, 143.6, 143.7, 146.2, 146.3, 155.9, 172.7.

Chiral HPLC Data

HPLC Conditions:

Chiral stationary phase: HPLC Chiralpack® AD-Hcolumn (*n*-hexane/isopropanol = 55:45, 0.70 mL/min) Wavelength = 254 nm tr = 13.649 min (major), >96% ee.



DL-3ai



Area% report for 3ai:

	Retention	Area	% Area	Height	% Height
	Time				
1	13.649	8539415	98.41	194855	98.25
2	15.803	138383	1.59	3462	1.75

HPLC Conditions:

Chiral stationary phase: HPLC Chiralpack® AD-Hcolumn (*n*-hexane/isopropanol = 50:50, 0.60 mL/min) Wavelength = 254 nm tr = 13.649 min (major), >93% ee.



Area%	report	for	5ai:

	Retention	Area	% Area	Height	% Height
	Time				
1	12.250	684089	2.49	16770	3.49
2	14.414	26801076	97.51	463730	96.51



Figure 1. ¹H NMR and ¹³C NMR spectra of 3aa



Figure 2. ¹H NMR and ¹³C NMR spectra of 3ab



Figure 3. ¹H NMR and ¹³C NMR spectra of 3ac



Figure 4. ¹H NMR and ¹³C NMR spectra of 3ad



Figure 5. ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra of 3ae





Figure 6. ¹H NMR and ¹³C NMR spectra of 3af



Figure 7. ¹H NMR and ¹³C NMR spectra of 3ag





Figure 8. ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra of 3ah

USER: nnr -- DATE: 09:41:16.703 +0100 nnr@EP-ZH109806

xxq-WZ CDC13,





Figure 9. ¹H NMR and ¹³C NMR spectra of 3ai



Figure 10. ¹H NMR and ¹³C NMR spectra of 3aj



Figure 11. ¹H NMR and ¹³C NMR spectra of 3ak



Figure 12. ¹H NMR and ¹³C NMR spectra of 3al



Figure 13. ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra of 3am

USER: nnr -- DATE: 18:01:44.375 +0100 nnr@EP-ZH109806

q-DSF CDC13,





Figure 14. ¹H NMR and ¹³C NMR spectra of 3an



Figure 15. ¹H NMR and ¹³C NMR spectra of 3ao

USER: nmr -- DATE: 16:04:30.812 +0100 nmr@EP-ZH109806

xxo-LB CDCI3.



Figure 16. ¹H NMR and ¹³C NMR spectra of 3ap



Figure 17. ¹H NMR and ¹³C NMR spectra of 3bj



Figure 18. ¹H NMR and ¹³C NMR spectra of 3cg



Figure 19. ¹H NMR and ¹³C NMR spectra of 4ai



Figure 20. ¹H NMR and ¹³C NMR spectra of 5ai